Olivia Brayer
Stock Analyst at Cantor Fitzgerald
(3.34)
# 1,011
Out of 5,030 analysts
105
Total ratings
47.62%
Success rate
4.58%
Average return
Main Sectors:
Stocks Rated by Olivia Brayer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CTMX CytomX Therapeutics | Initiates: Overweight | $6 | $3.20 | +87.50% | 1 | Sep 22, 2025 | |
| GOSS Gossamer Bio | Reiterates: Overweight | n/a | $2.19 | - | 1 | Sep 11, 2025 | |
| UTHR United Therapeutics | Maintains: Overweight | $405 → $525 | $433.34 | +21.15% | 2 | Sep 10, 2025 | |
| VNDA Vanda Pharmaceuticals | Assumes: Overweight | $13 | $5.27 | +146.68% | 1 | May 14, 2025 | |
| BMRN BioMarin Pharmaceutical | Reiterates: Overweight | $90 | $53.29 | +68.89% | 15 | Feb 20, 2025 | |
| VRTX Vertex Pharmaceuticals | Reiterates: Overweight | $480 | $416.81 | +15.16% | 22 | Feb 11, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Neutral | $50 → $55 | $43.63 | +26.06% | 9 | Feb 4, 2025 | |
| GILD Gilead Sciences | Reiterates: Neutral | $80 | $122.81 | -34.86% | 10 | Dec 11, 2024 | |
| OMER Omeros | Reiterates: Neutral | n/a | $8.11 | - | 1 | Nov 14, 2024 | |
| REGN Regeneron Pharmaceuticals | Reiterates: Neutral | $1,015 | $578.05 | +75.59% | 8 | Oct 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $405 | $298.81 | +35.54% | 2 | Oct 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $220 | $481.67 | -54.33% | 23 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $10 | $11.55 | -13.42% | 5 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $6.5 | $5.47 | +18.83% | 4 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $72 | $69.15 | +4.12% | 1 | Apr 13, 2023 |
CytomX Therapeutics
Sep 22, 2025
Initiates: Overweight
Price Target: $6
Current: $3.20
Upside: +87.50%
Gossamer Bio
Sep 11, 2025
Reiterates: Overweight
Price Target: n/a
Current: $2.19
Upside: -
United Therapeutics
Sep 10, 2025
Maintains: Overweight
Price Target: $405 → $525
Current: $433.34
Upside: +21.15%
Vanda Pharmaceuticals
May 14, 2025
Assumes: Overweight
Price Target: $13
Current: $5.27
Upside: +146.68%
BioMarin Pharmaceutical
Feb 20, 2025
Reiterates: Overweight
Price Target: $90
Current: $53.29
Upside: +68.89%
Vertex Pharmaceuticals
Feb 11, 2025
Reiterates: Overweight
Price Target: $480
Current: $416.81
Upside: +15.16%
Bristol-Myers Squibb Company
Feb 4, 2025
Maintains: Neutral
Price Target: $50 → $55
Current: $43.63
Upside: +26.06%
Gilead Sciences
Dec 11, 2024
Reiterates: Neutral
Price Target: $80
Current: $122.81
Upside: -34.86%
Omeros
Nov 14, 2024
Reiterates: Neutral
Price Target: n/a
Current: $8.11
Upside: -
Regeneron Pharmaceuticals
Oct 23, 2024
Reiterates: Neutral
Price Target: $1,015
Current: $578.05
Upside: +75.59%
Oct 22, 2024
Reiterates: Overweight
Price Target: $405
Current: $298.81
Upside: +35.54%
Oct 11, 2024
Reiterates: Neutral
Price Target: $220
Current: $481.67
Upside: -54.33%
Sep 16, 2024
Reiterates: Overweight
Price Target: $10
Current: $11.55
Upside: -13.42%
May 9, 2024
Reiterates: Overweight
Price Target: $6.5
Current: $5.47
Upside: +18.83%
Apr 13, 2023
Initiates: Overweight
Price Target: $72
Current: $69.15
Upside: +4.12%